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Abstract
Background: XMRV (xenotropic murine leukemia virus-related virus) was initially discovered in association with prostate
cancer and later with chronic fatigue syndrome (CFS). Its association with CFS is now largely discredited, and current results
support a laboratory origin for XMRV with no reproducible evidence for infection of humans. However, some results
indicating the presence of XMRV in prostate cancer are difficult to attribute to sample contamination. Here we have sought
biological evidence that might confirm the presence of XMRV in prostate cancer samples previously having tested positive.
Methods and Results: We have tested for infectious XMRV and neutralizing antibodies against XMRV in blood plasma from
29 subjects with prostate cancer, and for infectious XMRV in prostate secretions from another five prostate cancer subjects.
Nine of these subjects had previously tested positive for XMRV by PCR or by virus assay. We did not detect XMRV or related
retroviruses in any sample, and the neutralizing activities of the plasma samples were all very low, a result inconsistent with
XMRV infection of the plasma donors.
Conclusions: We find no evidence for XMRV infection of any human subject tested, either by assay for infectious virus or for
neutralizing antibodies. Our results are consistent with the majority of published studies on XMRV, which find that XMRV is
not present in humans. The observed low to undetectable XMRV neutralization by human plasma indicates a lack of innate
restriction of XMRV replication by soluble factors in human blood.
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Introduction
The retrovirus XMRV (xenotropic murine leukemia virus-
related virus) was initially discovered in human prostate cancer
samples [1] and was later found in the blood of a high percentage
of patients diagnosed with chronic fatigue syndrome (CFS) [2],
raising concern that XMRV was a new human pathogen.
However, the majority of subsequent studies have been unable
to detect XMRV in humans with or without prostate cancer [3] or
CFS [4]. In addition, the XMRV isolates from the early studies
were all nearly identical to a virus produced by a commonly used
prostate cancer cell line, 22Rv1 [5–7]. Perhaps XMRV was
present in the prostate cancer from which the 22Rv1 cells were
derived, but the lack of XMRV sequence diversity was puzzling
given the high mutation rate of retroviruses. Recently, the XMRV
present in 22Rv1 cells was shown to have arisen during passage of
the 22Rv1 prostate cancer cells and their ancestors in nude mice,
by a rare recombination event between two endogenous mouse
retroviruses, and was not detected in early xenografts of the
prostate tumor [8]. The expected rarity of this event and the lack
of sequence diversity in the ‘‘human’’ XMRV isolates [7,9] suggest
that the human samples were contaminated with the 22Rv1
XMRV or plasmid clones of XMRV.
Currently, a role for XMRV in CFS is largely disproven, and
the original paper that found this association has been retracted
[10]. In particular, a large collaborative study found that two of
the laboratory groups involved in the original research could not
reliably detect XMRV in patient samples, and that labs that could
reliably detect XMRV did not detect XMRV in patients with CFS
or in normal controls [11]. In the case of the association of XMRV
with prostate cancer, it is still unclear whether some of the original
prostate cancer samples might have contained patient-derived
XMRV or other related retroviruses.
Here we have analyzed blood plasma and expressed prostatic
secretions (EPS) from prostate cancer patients, some of whom
previously tested positive for XMRV [1,12–15], for the presence
of XMRV and related retroviruses by using an assay for infectious
retroviruses. In addition, we tested blood plasma for neutralizing
antibodies against XMRV that might limit our ability to detect
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against XMRV in the plasma donor. We find no evidence for
XMRV or related retroviruses, or a neutralizing antibody response
against XMRV, in any of the patient samples.
Results
XMRV Detection Methods
To detect infectious XMRV and related retroviruses in patient
plasma and EPS samples, we used S
+L
2 and marker rescue assays
that have been shown to effectively detect XMRV [5]. The S
+L
2
assay we used measures the ability of a retrovirus to infect and
cause spread of the Moloney murine sarcoma virus present in PG-
4 cat cells [16], leading to production of transformed foci in the
cell layer. The marker rescue assay was performed using Mus dunni
tail fibroblasts (dunni cells) transduced with a retroviral vector
(LAPSN) that produces human placental alkaline phosphatase
(AP). The dunni/LAPSN cells were exposed to test samples, were
passaged for a month to allow virus spread, and were assayed for
production of the LAPSN vector on naive dunni cells. Dunni cells
were chosen for this assay because of their susceptibility to a wide
range of murine leukemia viruses [17], including XMRV, other
xenotropic retroviruses, and polytropic retroviruses of the type
previously detected in humans [1,2,18]. To detect neutralizing
antibodies present in patient plasma samples, we used the S
+L
2
assay to quantitate replication-competent XMRV after incubation
with the samples, in comparison to XMRV incubated with culture
medium as a control. In some experiments, we measured the
ability of plasma to neutralize the LAPSN vector packaged in
XMRV virions (XMRV-pseudotype LAPSN vector) as a surrogate
for direct measurement of XMRV neutralization.
To determine the kinetics of virus spread and the sensitivity of
the marker rescue assay, the assay was conducted by exposing
dunni/LAPSN cells to 50, 25, 10, 5, 1, or 0 focus-forming units
(FFU) of XMRV, as determined by S
+L
2 assay. The cells were
then assayed weekly for LAPSN production during passage of the
cells for a month. LAPSN production was detected at one week
following infection with 50 FFU of XMRV, at 2 weeks following
infection with 10 and 5 FFU, and at 4 weeks for 1 of 2 plates
infected with 1 FFU of XMRV. These results show that the
marker rescue assay is approximately as sensitive as the S
+L
2 assay
for detection of XMRV. However, this marker rescue assay may
be more sensitive than the S
+L
2 assay for some retroviruses
because of the known sensitivity of dunni cells to a wide range of
murine retroviruses, while fewer types of murine retroviruses can
infect the cat cells used in the S
+L
2 assay.
No Evidence for XMRV Infection of Prostate Cancer
Patients
We first tested whether blood plasma from a set of ten prostate
cancer patients, three of whom previously tested positive for
XMRV by RT-PCR, contained replication-competent XMRV
and/or neutralizing antibodies against XMRV (Table 1). We did
not detect XMRV or related retroviruses in any sample by S
+L
2
assay. To detect neutralizing antibodies, plasma samples were
incubated at 1:10 and 1:100 dilutions with XMRV-pseudotype
LAPSN vector for 30 min at room temperature, and the
remaining LAPSN virus was measured by AP
+ focus assay. Only
one of the ten plasma samples showed weak neutralizing activity
(neutralizing titer of 10). This neutralizing activity was eliminated
by heat inactivation of the plasma, which inactivates complement,
showing that no antibodies were present that could directly block
virus infection.
Because of the low to undetectable level of neutralizing
antibodies in the first set of 10 patient samples, we conducted
additional neutralization assays using undiluted plasma. In
addition, we measured neutralization of XMRV virus as opposed
to the XMRV-pseudotype LAPSN vector. We did not detect
replication-competent XMRV or related retroviruses, by S
+L
2 or
marker rescue assays, in plasma from any of the 21 patients tested,
including four who previously tested positive for XMRV by PCR
(see Table 2 for patient and sample details). Furthermore, we
found little to no XMRV-neutralizing activity in the undiluted
plasma samples, even without heat treatment to inactivate
complement (Fig. 1). Sample VP950 showed the highest neutral-
izing activity (75% neutralization), but heat inactivation of the
sample before testing, or diluting the sample 10-fold before testing,
abolished the neutralizing activity (data not shown), indicating that
this activity is very weak and likely is dependent on complement.
The fact that infectious XMRV can persist following incubation
with the undiluted plasma samples indicates that infectious
XMRV could persist in the blood of these prostate cancer
patients, and would be detectable in our assays for replication-
competent virus. The apparent lack of a humoral immune
response against XMRV suggests that these patients are not
infected by XMRV, consistent with our inability to detect virus in
these plasma samples.
We next tested EPS fluids obtained from excised prostate glands
[13] for the presence of XMRV. To test for possible effects of EPS
on XMRV infectivity, we added a small amount of XMRV to
undiluted EPS from a normal prostate, or to culture medium as a
control, and measured the titer of these mixtures by using the
S
+L
2 assay. Duplicate samples for each mixture gave identical
results (XMRV titer of 5610
6 FFU/ml), showing that XMRV can
survive and be detected in EPS fluid. However, no replication-
competent virus was detected in any of 5 EPS samples from
prostate cancer patients by S
+L
2 or marker rescue assays (see
Table 2 for sample identifiers and amounts tested). Three of these
patients had previously tested positive for XMRV in urine
(Table 2) [15].
Activation of M. dunni Endogenous Retrovirus in Some
Marker Rescue Assays
We did experience some false positive results with the marker
rescue assay. In a few cases we detected LAPSN production
following exposure of dunni/LAPSN cells to plasma, but viral
interference analysis showed that LAPSN transduction was
completely blocked in dunni cells expressing the M. dunni
endogenous retrovirus (MDEV) [19,20], but was unaffected in
dunni cells expressing XMRV (data not shown). MDEV and
XMRV use different receptors for cell entry, which are blocked by
infection with the cognate retrovirus but are unaffected by
infection with the alternate virus [17]. To confirm that the
positive results were indeed artifactual, we performed a marker
rescue assay using DU145/LAPSN cells, and found that all of the
apparent false-positive patient samples were indeed negative for
replication-competent XMRV (data not shown). Previously,
MDEV production from M. dunni cells was observed following
treatment of the cells with 5-iodo-29-deoxyuridine or hydrocorti-
sone [19], and it appears that substances in the patient samples
have a similar ability to activate the normally silent MDEV locus
in dunni cells.
Discussion
Of the 29 plasma and 5 EPS samples from prostate cancer
patients that we tested, none had a detectable level of replication-
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plasma samples (VP29 and VP35) from patients who tested
XMRV positive by viral detection DNA microarray (Virochip)
analysis in the original study [1], one plasma sample (VP234) from
a patient who tested XMRV positive by RT-PCR of prostate
tissue RNA [12], one plasma sample (VP693) from a patient who
tested XMRV positive by RT-PCR of RNA isolated from EPS
[13], and one plasma sample (VP432) from a patient who tested
positive for infectious XMRV in plasma [14]. In particular, note
that prostate cancer tissue from patient VP35 was the presumed
source of the first full-length clone of XMRV [1]. Also included in
our analysis were three EPS samples (VP830, VP844 and VP881)
and one plasma sample (VP663) from patients who tested XMRV
positive by RT-PCR of RNA isolated from urine [15]. The S
+L
2
and dunni cell-based marker rescue assays that we used to detect
virus are both capable of detecting xenotropic and polytropic
retroviruses [5,17] of the types previously reported in prostate
cancer and CFS patients [1,2,18], as well as amphotropic murine
leukemia viruses. In addition, the S
+L
2 assay can detect RD114
feline retrovirus, feline leukemia virus types A, B and C, gibbon
ape leukemia virus, and Mus caroli endogenous retrovirus
(McERV) [16,17,21], thus the assays we used could have detected
the presence of a broad range of gamma retroviruses.
To determine whether XMRV could persist in blood and to
detect possible immune responses against XMRV, we assayed the
ability of blood plasma to neutralize XMRV infectivity. We
detected only minimal neutralization even under the most
stringent condition of incubating a small amount of XMRV with
undiluted, non-heat-inactivated plasma. At most, 75% of the
XMRV was neutralized after incubation with plasma, suggesting
that XMRV shed into the blood would have a long enough half-
life to allow detection. Indeed, 7 of 21 plasma samples assayed in
this way showed #10% neutralization (Fig. 1), indicating that
human plasma has little innate neutralizing activity against
XMRV. This result is consistent with a previous study of XMRV
neutralization by sera from CFS and normal subjects, which
showed 0 to 80% XMRV neutralization by undiluted non-heat-
inactivated sera, and no XMRV neutralization by heat-inactivated
sera [4], but is inconsistent with several other studies that detected
relatively high neutralization of XMRV by human plasma or
serum, even in those testing negative for XMRV by other criteria
[22–24]. For example, Groom et al. [22] found examples of
.50% neutralization of virus bearing XMRV Env proteins by
heat-inactivated serum at 1:40 and 1:80 dilutions, and most of
these positive results were from control subjects without prostate
cancer or CFS. However, most of the positive sera also neutralized
viruses bearing other Env proteins, including that of vesicular
stomatitis virus, showing the neutralizing activity was generally
nonspecific. Zhou et al. [24] found ,30% neutralization of virus
bearing XMRV Env by a 1:80 dilution of heat-inactivated serum,
with three sera showing ,50% neutralization. All other assays
performed indicated that all of these subjects were uninfected by
XMRV.
Several factors may explain the differences in neutralizing
antibody activities: i) heparin present in serum or plasma made
from blood collected in heparinized tubes can nonspecifically
inhibit virus infectivity, ii) repeated freezing and thawing of
samples can inactivate complement resulting in reduced neutral-
ization, iii) specific viral components of the virus used for
neutralization studies can affect the results (for example, use of
Gag proteins from HIV or other murine retroviruses in
combination with XMRV Env [22–24]), and iv) cellular factors
incorporated into virions during production of the virus used for
neutralization can affect the result [25–27]. In our study and the
study by Knox et al. [4], authentic XMRV produced from the
human prostate cancer cell line 22Rv1 was used in the
neutralization assays, while the studies of Groom et al. [22] and
Zhou et al. [24] utilized viruses made with Moloney Gag-Pol
proteins and XMRV Env, and were produced by transfection of
Table 1. Plasma samples from ten patients with prostate cancer do not contain infectious XMRV or related retroviruses and can
neutralize XMRV only partially if at all.
AP
+ foci for indicated plasma dilution
(HI = heat inactivated plasma)
{
Patient* RNase L genotype
{ S
+L
2 FFU in 30 ml plasma 1:10 1:100 HI 1:10 Neutralizing titer (no HI)
VP124 GA 0 85 161 210 10
VP234 AA 0 365 297 266 ,10
VP538 AA 0 368 340 224 ,10
VP627 GG 0 292 256 273 ,10
VP630 GG 0 320 320 257 ,10
VP653 GG 0 296 268 222 ,10
VP663 AA 0 380 286 280 ,10
VP673 GA 0 366 258 244 ,10
VP683 AA 0 320 250 280 ,10
VP693 GG 0 364 262 304 ,10
No plasma 233 233 188
*Patient identifiers shown in bold indicate patients who had previously tested positive for XMRV. See Discussion for details.
{Nucleotides at position 1385 of the RNase L coding regions of both patient alleles are shown. A G1385A transition at position 1385 results in a glutamine instead of
arginine at amino acid position 462 (R462Q) of RNase L, which has been associated with higher XMRV infection rates in homozygous R462Q patients in some studies [1].
{The virus neutralization assay was performed by incubating XMRV-pseudotype LAPSN vector (harvested from human cells infected with XMRV and the LAPSN vector)
with plasma samples at the indicated dilutions, or with phosphate-buffered saline as a no plasma control, for 30 min at room temperature. The remaining LAPSN virus
was measured by infection of HTX human fibrosarcoma cells and staining for foci of AP
+ cells two days later. Plasma heat inactivation was performed at 56uC for 30 min.
All dilutions were performed using phosphate-buffered saline.
doi:10.1371/journal.pone.0036073.t001
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could account for some of the nonspecific neutralization observed.
In summary, we did not detect replication-competent XMRV in
the plasma or EPS fluid from prostate cancer patients, nor did we
detect significant levels of neutralizing antibodies in plasma. These
data support the conclusion from other studies that XMRV has
not entered the human population.
Materials and Methods
Human Subjects
Blood plasma and expressed prostatic fluid (EPS) samples used
in the current study were obtained at the Cleveland Clinic
following approval by the Cleveland Clinic Foundation Institu-
tional Review Board. All samples were obtained from subjects with
prostate cancer after written informed consent was obtained.
Plasma samples were prepared from blood collected in standard
EDTA tubes, EPS fluid was obtained by massage of excised
prostate glands after prostatectomy, and all samples were stored at
270uC. Many of the plasma samples were frozen and thawed
once for analysis, while others were frozen and thawed a limited
number of times (Table 2).
Cell Culture
M. dunni tail fibroblasts (dunni cells) [28], 293 human embryonic
kidney cells [29], 22Rv1 prostate carcinoma cells (ATCC CRL-
2505), HTX cells (an approximately diploid subclone of HT-1080
human fibrosarcoma cells) [5] and DU145 prostate cancer cells
[30] were grown in Dulbecco’s modified Eagle’s medium with
4.5 g/l glucose and 10% fetal bovine serum (FBS). PG-4 feline
cells [16] were grown in McCoy’s medium with 15% FBS. XMRV
virus used in this study was harvested from 22Rv1 cells obtained
directly from the ATCC.
S
+L
2 and XMRV Neutralization Assays
PG-4 cells were seeded at 2.5610
5 per 6-cm dish on day 1. On
day 2, plasma and EPS samples were thawed and portions of each
Table 2. Characteristics of plasma and EPS samples tested for infectious XMRV and related retroviruses.
Patient* RNase L genotype
{ Sample Times frozen
Amount tested by S+L2 assay
(ml)
Amount tested by marker rescue
assay (ml)
VP29 AA Plasma 1 100 100
VP35 AA Plasma 1 100 100
VP124 GA Plasma 1 100 100
VP234 AA Plasma 1 100 100
Plasma 2 80 80
VP432 AA Plasma 2 100 100
VP830 GA EPS 2 30 30
VP844 GG EPS 2 50 50
EPS 3 12 12
VP847 AA EPS 2 30 30
EPS 3 20 20
VP875 AA EPS 2 50 50
EPS 3 10 10
Plasma 1 50 50
VP881 GA EPS 2 30 30
VP882 GA Plasma 1 50 50
VP888 AA Plasma 1 50 50
VP897 AA Plasma 1 50 50
VP898 AA Plasma 1 50 50
VP918 AA Plasma 1 50 50
VP922 AA Plasma 1 50 50
VP924 GG Plasma 1 50 50
VP926 AA Plasma 1 100 100
VP931 AA Plasma 1 100 100
VP934 AA Plasma 1 100 100
VP935 AA Plasma 1 100 100
VP949 AA Plasma 1 100 100
VP950 AA Plasma 1 100 100
VP964 GG Plasma 1 100 100
VP967 AA Plasma 1 100 100
*Patient identifiers shown in bold indicate patients who had previously tested positive for XMRV. See Discussion for details.
{Nucleotides at position 1385 of the RNase L coding regions of both patient alleles are shown. See Table 1 footnotes for additional details.
doi:10.1371/journal.pone.0036073.t002
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with a small volume of infectious XMRV (harvested from 22Rv1
cells) for 15 to 30 minutes at room temperature, while the other
portions of the plasma and EPS samples were kept on ice. Virus-
spiked and untreated samples were added to the PG-4 cells in the
presence of 4 mg/ml Polybrene. Cells were fed on day 3, and foci
were counted on day 4 or 5. In some experiments the plasma was
heat-inactivated at 56uC for 30 min before assay for virus
neutralization.
Marker Rescue Assay
Dunni and DU145 cells containing the LAPSN retroviral
vector (dunni/LAPSN and DU145/LAPSN cells) were generated
by exposing cells to helper-free LAPSN vector generated from
PA317 retrovirus packaging cells [31] and then selecting the cells
in G418 for 1 week to ensure the presence of the vector in all
cells in the populations. The marker rescue assay was performed
as follows. Dunni/LAPSN or DU145/LAPSN cells were seeded
at 5610
5 per 6-cm dish on day 1 and were exposed to test
samples (blood plasma or EPS) in the presence of 4 mg/ml
Polybrene on day 2. The cells were then passaged for a month at
high density (to facilitate virus spread) by trypsinizing and
reseeding the cells at a 1:10 dilution every time the cells became
confluent. LAPSN production was then measured by feeding
confluent cells, harvesting the medium the next day, removing
cells by filtration (0.2 mm-pore-size surfactant-free cellulose
acetate filters) or by centrifugation (4,0006g for 15 min), by
adding medium samples with 4 mg/ml Polybrene to dunni or 293
cells seeded the day before at 5610
4 per well of 12-well plates,
and by staining the cells for AP two days later.
Virus Interference Assay
Replicating virus detected in the marker rescue assay was
subjected to interference analysis using dunni cells chronically
infected with either XMRV from 22Rv1 cells or with the M. dunni
endogenous retrovirus (MDEV) from dunni cells. On day 1 the
infected and uninfected dunni cells were seeded in 12-well dishes
at 5610
4 per well. On day 2, the medium was replaced with 1 ml
of medium containing 4 mg of Polybrene and 0.1 ml of medium
harvested from the marker rescue assay cells. On day 4, the cells
were stained for AP. The MDEV-infected dunni cells are resistant
to MDEV but permissive to XMRV while the XMRV-infected
dunni cells are resistant to XMRV but permissive to MDEV.
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